Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase 3 INSTRIDE 2 study

Blevins TC et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13495

Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.

https://doi.org/10.1111/dom.13495